Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
10x Genomics develops and commercializes single-cell and spatial genomics platforms used by research institutions and biopharma companies for drug discovery, oncology research, and immunology studies. The company generates revenue through instrument sales (Chromium controllers, Visium spatial platforms) and recurring consumables (microfluidic chips, reagent kits), with consumables representing approximately 75-80% of revenue. Despite strong gross margins near 70%, the company remains unprofitable as it invests heavily in R&D for next-generation spatial biology platforms and expands commercial infrastructure globally.
10x Genomics operates a razor-razorblade model where instruments are sold at modest margins to establish installed base, then generates high-margin recurring revenue from proprietary consumables. Each Chromium or Visium workflow requires specific microfluidic chips and reagent kits that cannot be substituted. Pricing power derives from technological differentiation in single-cell resolution and spatial transcriptomics capabilities that competing platforms cannot match. Average consumable revenue per instrument ranges $150K-$250K annually depending on utilization. The company faces limited competition in spatial genomics (primarily NanoString, acquired by Bruker) but competes with Illumina, BD Biosciences, and Parse Biosciences in single-cell sequencing.
Consumables revenue growth rate and attach rates per installed instrument - indicates customer utilization and workflow adoption
New instrument placements, particularly Visium spatial platforms and Xenium in-situ systems which drive higher consumable pull-through
Biopharma funding environment and NIH/academic research budgets - 60-70% of customers are research institutions dependent on grant funding
Product launch timelines for next-generation platforms and competitive positioning versus Illumina's single-cell offerings
Gross margin trends reflecting product mix shift toward higher-margin spatial products versus legacy Chromium consumables
Technological obsolescence risk as sequencing costs decline and alternative single-cell methods (Parse Biosciences' combinatorial barcoding, BD Biosciences' Rhapsody) offer lower-cost workflows that could commoditize the market
Regulatory risk if spatial genomics platforms are used for clinical diagnostics - would require FDA clearance and quality system compliance, significantly increasing operational complexity
Customer concentration in academic/government research (60-70% of revenue) creates vulnerability to NIH budget cuts or shifts in research priorities away from single-cell genomics
Illumina's entry into spatial genomics through acquisitions and internal development could leverage its dominant sequencing installed base to bundle offerings and pressure 10x pricing
Bruker's acquisition of NanoString (GeoMx platform) creates better-capitalized competitor in spatial transcriptomics with established biopharma relationships
Open-source and lower-cost single-cell methods gaining traction in price-sensitive academic markets, potentially limiting instrument placements outside top-tier institutions
Cash burn of approximately $40-60M per quarter requires careful capital management - at current burn rate, existing cash provides 2.5-3 year runway without achieving profitability
Inventory risk as product transitions occur - obsolescence reserves required if Chromium platforms are displaced by next-generation systems
Minimal debt (Debt/Equity 0.20) reduces financial risk but limits financial flexibility if equity markets remain unfavorable for capital raises
moderate - Revenue is partially insulated by long research cycles and multi-year grant funding, but discretionary capital equipment purchases by academic labs and biotech companies decline during economic downturns. Biopharma R&D spending tends to be more resilient than broader economy, but early-stage biotech funding (venture capital, IPOs) is highly cyclical and impacts customer budgets. Approximately 30-40% of revenue comes from biopharma which is less cyclical than academic/government customers.
Rising interest rates negatively impact 10x Genomics through multiple channels: (1) biotech venture funding contracts sharply in high-rate environments, reducing customer budgets for genomics tools, (2) academic endowment returns compress, constraining research spending, (3) valuation multiples for unprofitable growth companies contract as discount rates rise. The company's own financing costs are minimal given low debt levels, but customer financing constraints are material. The 2022-2023 biotech funding drought directly impacted instrument sales.
Minimal direct credit exposure - customers are primarily research institutions and established biopharma with low default risk. No meaningful accounts receivable financing or customer credit extension. However, indirectly exposed to credit conditions through biotech sector access to venture debt and equity financing.
growth - Investors are betting on long-term market expansion in spatial biology and single-cell genomics becoming standard research tools, accepting near-term losses for potential market leadership. The 54% one-year return and strong recent momentum attracts growth and momentum investors. Negative earnings and high P/S ratio (3.7x) exclude value investors. No dividend, purely capital appreciation thesis.
high - Small-cap biotech tools company with $2.4B market cap exhibits significant volatility driven by quarterly revenue beats/misses, product launch announcements, and broader biotech sector sentiment. Beta likely 1.3-1.6 range. Stock highly correlated with ARK Genomic Revolution ETF and biotech innovation indices. Recent 18.6% three-month return demonstrates momentum-driven trading patterns.
